Aprea
Karolinska Institutet Science Park
Nobels väg 3
Solna
SE-171 65
Tel: 46-0-8-50884504
Fax: 46-0-8-52487022
Website: http://aprea.com/
59 articles about Aprea
-
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
3/11/2024
Aprea Therapeutics, Inc. today announced that it has entered into a securities purchase agreement with new and existing healthcare focused institutional investors and certain Company insiders to raise up to $34.0 million in gross proceeds, including initial upfront funding of $16.0 million and up to an additional $18.0 million upon cash exercise of accompanying warrants at the election of the investors.
-
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
3/11/2024
Aprea Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application (IND 169359) for APR-1051.
-
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
3/5/2024
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, announced four poster presentations at the American Association of Cancer Research Annual Meeting, to take place April 5 to 10, 2024 in San Diego, CA.
-
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
2/6/2024
Aprea Therapeutics, Inc. today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to initiate clinical trials of APR-1051.
-
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
11/9/2023
Aprea Therapeutics, Inc. reported financial results for the three and nine months ended September 30, 2023, and provided a business update.
-
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
10/24/2023
Aprea Therapeutics, Inc. announced it will host a KOL event on Tuesday, October 31, 2023 at 11:00 am ET. The program will feature Dr. Fiona Simpkins, Perelman School of Medicine, University of Pennsylvania, and Dr. Timothy A. Yap, University of Texas MD Anderson Cancer Center, who will discuss the current landscape of treatments and investigational drugs for patients with advanced solid tumors and their role in tumor suppression.
-
Aprea Therapeutics to Present at BIO International Convention
5/30/2023
Aprea Therapeutics, Inc. today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present a corporate overview at the BIO International Convention, being held in Boston, Massachusetts from June 5-8, 2023.
-
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
5/15/2023
Aprea Therapeutics, Inc. reported financial results for the three months ended March 31, 2023 and provided a business update.
-
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
3/30/2023
Aprea Therapeutics, Inc. reported financial results for the three months and year ended December 31, 2022 and provided a business update.
-
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
2/27/2023
Aprea Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 1,050,000 shares of its common stock at a public offering price of $5.25 per share.
-
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
1/11/2023
Aprea Therapeutics, Inc. today announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead ATR inhibitor for the treatment of cancers with DDR mutations.
-
Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
8/2/2022
Aprea Therapeutics, Inc. today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will participate in a panel discussion on synthetic lethality at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022 at 12:35 p.m. ET.
-
Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022
1/6/2022
Aprea Therapeutics will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 11:15 a.m. ET.
-
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
12/13/2021
Aprea Therapeutics, Inc. today announced updated results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML at the 2021 ASH Annual Meeting.
-
Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting
11/4/2021
Aprea Therapeutics, Inc. today announced that investigators will present data from clinical trials evaluating eprenetapopt at the 63rd American Society of Hematology Annual Meeting (ASH).
-
Aprea’s clinical trial is evaluating a combination of eprenetapopt with acalabrutinib or with venetoclax and rituximab.
-
Aprea faces another disappointment this week in the clinic. The FDA held up a yellow card, and the Boston-based biotech has placed a partial clinical hold on its myeloid malignancy program.
-
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
7/21/2021
Aprea Therapeutics, Inc. today announced positive results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML.
-
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
6/16/2021
Aprea Therapeutics, Inc. today announced that the Phase 1/2 trial evaluating the frontline treatment of eprenetapopt with venetoclax and azacitidine in patients with TP53 mutant AML has met the pre-specified primary efficacy endpoint of complete remission rate.
-
Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit
5/21/2021
Aprea Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, announced that Greg Korbel, Senior Vice President and Chief Business Officer, will present a corporate update at the 2021 Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 3:45 p.m. ET.